User login
Is it all or nothing when it comes to quitting smoking?
For many smokers, there may be another approach: A new study showed that a 24-week course of varenicline boosted quit rates among smokers who preferred to gradually reduce their cigarette use (JAMA 2015;313:687-94). That behavioral health reduction strategy may offer 14 million smokers an alternative route to quitting, noted study author Dr. Jon O. Ebbert of the Mayo Clinic, Rochester, Minn.
In a video interview, Dr. Ebbert discusses the strategy and its benefits.
Dr. Ebbert reported receiving grants from Pfizer, JHP Pharmaceuticals, and Orexigen, as well as personal fees from GlaxoSmithKline.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
Is it all or nothing when it comes to quitting smoking?
For many smokers, there may be another approach: A new study showed that a 24-week course of varenicline boosted quit rates among smokers who preferred to gradually reduce their cigarette use (JAMA 2015;313:687-94). That behavioral health reduction strategy may offer 14 million smokers an alternative route to quitting, noted study author Dr. Jon O. Ebbert of the Mayo Clinic, Rochester, Minn.
In a video interview, Dr. Ebbert discusses the strategy and its benefits.
Dr. Ebbert reported receiving grants from Pfizer, JHP Pharmaceuticals, and Orexigen, as well as personal fees from GlaxoSmithKline.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
Is it all or nothing when it comes to quitting smoking?
For many smokers, there may be another approach: A new study showed that a 24-week course of varenicline boosted quit rates among smokers who preferred to gradually reduce their cigarette use (JAMA 2015;313:687-94). That behavioral health reduction strategy may offer 14 million smokers an alternative route to quitting, noted study author Dr. Jon O. Ebbert of the Mayo Clinic, Rochester, Minn.
In a video interview, Dr. Ebbert discusses the strategy and its benefits.
Dr. Ebbert reported receiving grants from Pfizer, JHP Pharmaceuticals, and Orexigen, as well as personal fees from GlaxoSmithKline.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
FROM JAMA
